Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol SERTAD1 contributors: mct - updated : 26-08-2019
HGNC name SERTA domain containing 1
HGNC id 17932
Location 19q13.2      Physical location : 40.928.410 - 40.931.932
Genatlas name CDK4 binding protein p34
Synonym name
  • CDK4-binding protein p34SEI
  • transcriptional regulator interacting with the PHD-bromodomain 1
  • Synonym symbol(s) SEI1, TRIP-Br1, TRIPBR1
    DNA
    TYPE functioning gene
    STRUCTURE 4.40 kb     2 Exon(s)
    MAPPING cloned Y linked N status provisional
    RNA
    TRANSCRIPTS type messenger
    identificationnb exonstypebpproduct
    ProteinkDaAAspecific expressionYearPubmed
    2 - 2084 - 236 - 2019 30230528
    - - - 34 - - 2013 23970032
  • oncoprotein that has multiple important biological functions
  • affects the subcellular localization of PTEN
  • EXPRESSION
    Type widely
       expressed in (based on citations)
    organ(s)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Digestiveintestinesmall intestine  highly
    Lymphoid/Immunetonsils   highly
    Reproductivefemale systemovary  highly
    tissue
    SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
    Connectivebone  highly
    cell lineage
    cell lines
    fluid/secretion
    at STAGE
    PROTEIN
    PHYSICAL PROPERTIES
    STRUCTURE
    motifs/domains
  • a conserved PHD-Bromo binding domain
  • an interaction module for bromodomain-containing proteins
  • a SERTA domain
  • HOMOLOGY
    Homologene
    FAMILY SERTA domain family of proteins
    CATEGORY regulatory
    SUBCELLULAR LOCALIZATION     intracellular
    intracellular,cytoplasm
    intracellular,nucleus
    basic FUNCTION
  • antagonizing the function of CDKN2A
  • involved in cell cycle regulations by interacting with a number of important proteins including CDK4
  • both SERTAD1 and SERTAD2 are required for proper transduction of mitogenic signals and execution of serum-inducible cell cycle progression
  • SERTAD1 expression is required for developmental neuronal death in the cerebral cortex
  • plays an essential role in developmental and pathological neuron death
  • SERTAD1 acts likely as a SMAD1 transcriptional co-activator to promote the expression of BMP target genes during cardiogenesis
  • inhibits autophagy, apoptosis, and necroptosis under nutrient/serum-deprived condition
  • functions likely as an oncogenic protein by providing cancer cells resistance to the hypoxia-induced cell death
  • activate transcription when recruited to a target promoter
  • role in the regulation of genomic stability and in the malignant progression of ovarian cancer
  • is a novel AR-LBD-binding protein
  • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • interacting with CDK4 (regulates the kinase activity of cyclin-dependent kinase 4 in a concentration-dependent manner)
  • interacting with CREBBP (association with CREBBP is not only involved in cell cycle regulation by CREBBP, but also have some effect on other CREBBP-dependent transcription)
  • also interacts with CDKN3, a bromodomain-containing corepressor suggesting that not all bromodomains are associated with transcriptional activation only
  • MDFI and MDFIC specifically interact with SERTAD1 through their C-terminal I-mfa domains
  • may render cancer cells resistant to apoptosis through the stabilization of XIAP
  • SERTAD1 acts as an adaptor that bridges the interaction of multiple Adenylyl cyclases (ACs) isoforms with XIAP, a RING-domain E3 ubiquitin ligase
  • direct interaction between human NEDD4 and SERTAD1
  • is a novel AR-binding protein that binds to the AR ligand binding domain (LBD)
  • cell & other
    REGULATION
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    tumoral     --over  
    in ovarian carcinomas
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancerreproductiveprostate
    may represent a novel therapeutic target for the treatment of AR-positive prostate cancer
    ANIMAL & CELL MODELS